HER2 Support Group Forums - View Single Post - A must watch - Risk Breast cancer and vitamin D 50-80% risk reduction

R.B. · 08-11-2009, 02:14 PM

Thank you very much Ted for those excellent links and particularly the July !!!! 2009 paper from Mount Sinai.http://www.mshri.on.ca/ on intakes.

That was very well spotted 10/10.

http://www.ncbi.nlm.nih.gov/pubmed/1...ubmed_RVDocSum

I have seen that sentiment expressed on a number of occasions but not in such direct terms or by such a well regarded institution.

I have copied it so people can see it for themselves and ask their medical advisers what they think.

Ann Epidemiol. 2009 Jul;19(7):441-5. Epub 2009 Apr 11.Click here to read Links
Vitamin D and cancer mini-symposium: the risk of additional vitamin D.
Vieth R.

Department of Nutritional Sciences, University of Toronto, and Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada. rvieth@mtsinai.on.ca

Any benefit of vitamin D needs to be balanced against the risk of toxicity, which is characterized by hypercalcemia. Daily brief, suberythemal exposure of a substantial area of the skin to ultraviolet light, climate allowing, provides adults with a safe, physiologic amount of vitamin D, equivalent to an oral intake of about 10,000 IU vitamin D(3) per day, with the plasma 25-hydroxyvitamin D (25(OH)D) concentration potentially reaching 220 nmol/L (88 ng/mL). The incremental consumption of 40 IU/d of vitamin D(3) raises plasma 25(OH)D by about 1 nmol/L (0.4 ng/mL). High doses of vitamin D may cause hypercalcemia once the 25(OH)D concentration is well above the top of the physiologic range. The physiological buffer for vitamin D safety is the capacity of plasma vitamin D-binding protein to bind the total of circulating 25(OH)D, vitamin D, and 1,25-dihydroxyvitamin D [1,25(OH)2D]. Hypercalcemia occurs when the free concentration is inappropriately high because vitamin D and its other metabolites have displaced 1,25(OH)2D from vitamin D-binding protein. Evidence from clinical trials shows, with a wide margin of confidence, that a prolonged intake of 10,000 IU/d of vitamin D(3) poses no risk of adverse effects for adults, even if this is added to a rather high physiologic background level of vitamin D.

08-11-2009, 02:14 PM	#6
R.B. Senior Member Join Date: Mar 2006 Posts: 1,843	Re: A must watch - Risk Breast cancer and vitamin D 50-80% risk reduction Thank you very much Ted for those excellent links and particularly the July !!!! 2009 paper from Mount Sinai.http://www.mshri.on.ca/ on intakes. That was very well spotted 10/10. http://www.ncbi.nlm.nih.gov/pubmed/1...ubmed_RVDocSum I have seen that sentiment expressed on a number of occasions but not in such direct terms or by such a well regarded institution. I have copied it so people can see it for themselves and ask their medical advisers what they think. Ann Epidemiol. 2009 Jul;19(7):441-5. Epub 2009 Apr 11.Click here to read Links Vitamin D and cancer mini-symposium: the risk of additional vitamin D. Vieth R. Department of Nutritional Sciences, University of Toronto, and Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada. rvieth@mtsinai.on.ca Any benefit of vitamin D needs to be balanced against the risk of toxicity, which is characterized by hypercalcemia. Daily brief, suberythemal exposure of a substantial area of the skin to ultraviolet light, climate allowing, provides adults with a safe, physiologic amount of vitamin D, equivalent to an oral intake of about 10,000 IU vitamin D(3) per day, with the plasma 25-hydroxyvitamin D (25(OH)D) concentration potentially reaching 220 nmol/L (88 ng/mL). The incremental consumption of 40 IU/d of vitamin D(3) raises plasma 25(OH)D by about 1 nmol/L (0.4 ng/mL). High doses of vitamin D may cause hypercalcemia once the 25(OH)D concentration is well above the top of the physiologic range. The physiological buffer for vitamin D safety is the capacity of plasma vitamin D-binding protein to bind the total of circulating 25(OH)D, vitamin D, and 1,25-dihydroxyvitamin D [1,25(OH)2D]. Hypercalcemia occurs when the free concentration is inappropriately high because vitamin D and its other metabolites have displaced 1,25(OH)2D from vitamin D-binding protein. Evidence from clinical trials shows, with a wide margin of confidence, that a prolonged intake of 10,000 IU/d of vitamin D(3) poses no risk of adverse effects for adults, even if this is added to a rather high physiologic background level of vitamin D. Last edited by R.B.; 08-11-2009 at 02:42 PM..